U.S. stock market midday update: Executive sell-off triggers trust crisis, Equillium's stock price plummets 8.39%

U.S. Stock Market Midday Update Equillium fell 8.39%. Based on recent key news: On December 23, Christine Zedelmayer, Senior Vice President and Chief Operating Officer of Equillium, reported the sale of the company's common stock. This move may lead to a lack of confidence among market insiders, resulting in a decline in stock price. According to disclosures from the EDGAR system, Equillium's stock price dropped 8.39%. The recent volatility in the biotech sector requires attention. Stocks with High Trading Volume in the Industry AbbVie fell 0.28%. Based on recent key news: On December 25, analyst ratings showed that AbbVie was not listed among the top five recommended buy stocks. Although AbbVie currently has a moderate buy rating among analysts, top analysts believe there are five other stocks that are more worthy of investment, which may weaken investor confidence in AbbVie and affect its stock price. No other significant news recently. Market fund flows indicate active trading. Regeneron Pharmaceuticals fell 0.43%. Based on recent news: On December 26, MarketBeat reported that Regeneron Pharmaceuticals was not included in the list of five stocks recommended by top analysts. Although Regeneron currently has a moderate buy rating among analysts, top analysts believe there are five stocks that are more worthy of purchase. This news may lead to a decline in investor confidence and a drop in stock price. On December 24, Wells Fargo analysts maintained a neutral rating on Regeneron Pharmaceuticals with a target price of $745. BMO Capital analysts continued to hold an outperform rating with a target price of $850. Morgan Stanley analysts also maintained a neutral rating with a target price of $768. The divergence in analyst ratings may create uncertainty in the market regarding Regeneron's prospects, affecting stock performance. Caution is advised regarding the differing views on Regeneron's outlook. Gilead Sciences fell 0.91%. Based on recent key news: On December 24, Gilead Sciences announced the acquisition of Repare Therapeutics' polymerase ATPase inhibitor RP-3467 for up to $30 million. This move indicates Gilead's strategic expansion in the cancer treatment field, leading to stock price fluctuations. On December 24, Repare Therapeutics' stock price rose over 20% due to the sale of RP-3467 to Gilead, enhancing Repare's cash flow and indirectly impacting Gilead's market performance. On December 24, analysts maintained a moderate buy rating on Gilead but noted that five other stocks are more valuable for investment, which may put pressure on Gilead's stock price. The pharmaceutical industry is active in mergers and acquisitions, with significant capital flow Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen fell 0.82%. Based on recent key news: On December 27, Amgen's third-quarter revenue grew by 4.1%, reaching $9.56 billion, exceeding market expectations. This growth was primarily driven by the FDA approval of the new drug Uplizna, which is used to treat chronic neuromuscular diseases, enhancing Amgen's risk/reward appeal. Source: Seeking Alpha On December 26, analysts rated Amgen as a moderate buy but noted that five other stocks have greater investment value. This may have affected investor confidence in Amgen, leading to a decline in its stock price. Source: Seeking Alpha No other significant news recently. The biopharmaceutical industry faces risks from policy changes